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Abstract
Objective—To characterize human triglyceride-rich lipoproteins (TRL) with and without apoA-
II and to study their metabolism in vivo.
Methods—Plasma from 11 participants on a controlled diet given a bolus infusion of [D5]L-
phenylalanine to label apoB was combined into four pools and applied to anti-apoA-II 
immunoaffinity columns. Fractions with and without apoA-II were separated into VLDL and IDL 
by ultracentrifugation; lipids and apolipoproteins were measured. For kinetic measurements, apoB 
was isolated and hydrolyzed to the constituent amino acids. Tracer enrichment was measured by 
GCMS. Metabolic rates were determined by SAAM-II.
Results—VLDL and IDL with apoA-II comprised 7% and 9% of total VLDL and IDL apoB 
respectively. VLDL with apoA-II was enriched in apoC-III, apoE, and cholesterol compared to 
VLDL without apoA-II. Mean apoB FCR of VLDL with apoA-II was significantly lower than for 
VLDL without apoA-II (2.80±0.96 pools/day v.s. 5.09±1.69 pools/day, P=0.009). A higher 
percentage of VLDL with apoA-II was converted to IDL than was cleared from circulation, 
compared to VLDL without apoA-II (96±8% vs. 45±22%; P=0.007). The rate constants for 
conversion of VLDL to IDL were similar for VLDL with and without apoA-II. Thus, a very low 
rate constant for clearance accounted for the lower FCR of VLDL with apoA-II.
Conclusion—VLDL with apoA-II represents a small pool of VLDL particles that has a slow 
FCR and is predominantly converted to IDL rather than cleared from the circulation.
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Introduction
Apolipoprotein A-II (apoA-II) is the second most abundant protein constituent of high-
density lipoprotein (HDL), accounting for about 20% of HDL protein.1 The mean plasma 
total apoA-II concentration is about 30–35mg/dL.2 Although apoA-II is mainly found 
associated with HDL, a small proportion is associated with the apoB lipoproteins, especially 
chylomicrons and very-low-density lipoprotein (VLDL).3
Animal models have shown that apoA-II can directly affect VLDL metabolism.4–6 
Transgenic mice expressing human apoA-II at two to three times higher than the normal 
concentration of mouse apoA-II displayed hypertriglyceridemia.4 The lipoprotein lipase 
mediated lipolysis of VLDL particles containing apoA-II was impaired in these mice.4 
Secretion of VLDL was not affected.4 A subsequent study confirmed that human apoA-II 
transgenic mice had reduced hydrolysis of triglycerides from chylomicrons and VLDL, but 
also found a 25% increase in triglyceride secretion.5 These findings suggest that the 
hypertriglyceridemia in human apoA-II overexpressing mice is associated with increased 
secretion and defective catabolism by lipoprotein lipase of triglyceride-rich lipoproteins.
The role of apoA-II in human VLDL metabolism is unclear. Patients who have severe 
hypertriglyceridemia (Type V hyperlipoproteinemia) have apoB lipoproteins that are 
enriched in apoA-II that are poor substrates for lipoprotein lipase. 3 Patients with Tangier 
disease have VLDL that contain a large amount of apoA-II that is also a poor substrate for 
lipoprotein lipase, and they have mild hypertriglyceridemia.3,7 Alaupovic et al separated 
apoB lipoproteins from patients with severe hypertriglyceridemia or Tangier disease into 
lipoproteins with or without apoA-II.3 Importantly, the apoB lipoproteins from both groups 
that contained apoA-II had impaired reactivity to lipoprotein lipase compared to lipoproteins 
that did not contain apoA-II.3 In other respects, the lipid and apolipoprotein composition of 
the apoB lipoproteins that had apoA-II was similar to VLDL that did not have apoA-II. 
These studies in mice and humans raise the possibility that apoA-II contributes to 
hypertriglyceridemia by reducing lipolysis in plasma of triglyceride-rich lipoproteins. It is 
also possible that apoA-II, as a surface protein, interferes with clearance of VLDL from the 
circulation by apoE or apoB interacting with hepatic receptors, similar to the action of 
another VLDL surface protein, apoC-III.8
It is unknown whether apoA-II affects VLDL metabolism in normolipidemia or in common 
phenotypes of mild hypertriglyceridemia. No studies have directly examined the relationship 
of apoA-II to VLDL metabolism in vivo in humans. To do this, we studied the metabolism 
of VLDL and IDL that contain apoA-II compared to those that do not have apoA-II in 
individuals who have normal or mildly increased fasting triglyceride levels.
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Materials and Methods
Subjects
11 participants evaluated were recruited as part of a previous study. 8,9 Exclusion criteria 
included secondary hyperlipidemia; Apo E2/E2, E4/E4, and E2/E4 genotypes and use of 
medications that affect lipid metabolism. The study was approved by the Human Subjects 
Committees at Harvard School of Public Health and Brigham and Women’s Hospital. All 
participants gave informed consent.
Dietary Period
All study subjects were provided complete diets rich in either monounsaturated fat or 
carbohydrate for 3 weeks before the kinetic study. The participants as outpatients were 
required to eat one meal each weekday on-site, either lunch or dinner. The monounsaturated 
fat diet consisted of 37% fat (8% saturated fat, 24% monounsaturated fat, and 5% 
polyunsaturated fat), 48% carbohydrate, and 15% protein. The carbohydrate diet consisted 
of 20% fat (7% saturated fat, 8% monounsaturated fat, and 5% polyunsaturated fat), 65% 
carbohydrate, and 15% protein. Participants were instructed not to consume alcohol or 
intake any other source of calories. Energy intake was adjusted to keep body weight constant 
during the study period.
Kinetic Study
Participants received a bolus injection of 1.2 µmol/kg [D5] L-phenylalanine (Tracer 
Technologies, Cambridge, MA). Blood samples were collected every 30 minutes for the first 
two hours and hourly thereafter for a total of 14 hours. To maintain a constant postprandial 
state, small hourly meals were consumed. The daily intake was divided into 12 portions to 
obtain the hourly intake level. Hourly food intake started 3 hours before the tracer was 
administered. This technique has been used previously by Zheng et al. in the same kinetic 
protocol with these participants.9
Separation of Lipoproteins
Because the plasma from these participants in this kinetics protocol was obtained and used 
in a previous study, quantities were limited. A pooling scheme was therefore devised to 
create enough sample at baseline and at each time point during the tracer infusion so that the 
lipoprotein fractionation could yield sufficient quantity for measurements of tracer 
enrichment and composition of apoA-II containing VLDL which we determined had a very 
low plasma concentration. The 11 participants were divided into four groups each with 2–3 
individuals and their plasma was combined to create 4 pools for analysis of kinetics and 
composition. One pool came from normolipidemic participants (N=3), and three came from 
mildly hypertriglyceridemic participants (N=2, 3, 3). Two pools each came from participants 
on the low-fat diet and the high-monounsaturated fat diets (Table 1). The availability of 
sufficient plasma governed the selection of the specific participants that were pooled. We 
emphasize that the aim of this study was to compare the kinetics of TG-rich lipoproteins that 
contained apoA-II with those that did not apoA-II, and not to explore modulation of the 
kinetics by diet type for which this protocol is not suited. Another reason for pooling is to 
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reduce the between-subjects variability in kinetic parameters, and to reduce the chance of 
outliers.
An equal amount of plasma from each individual in a group was pooled for each time point. 
Pooled plasma from each time point was loaded into 20 mL Econo-Pac columns (Bio-Rad 
Laboratories, Hercules, CA) packed with 2.5mL of anti–apoA-II resin prepared from 
polyclonal sheep anti–human apoA-II antibody bound to Sepharose 4B Resin at a minimum 
concentration of 10 mg antibody/mL resin (Academy Biomedical Company Inc, Houston, 
TX). Samples and resin were incubated for 16 hours at 4 °C with mixi ng. The unbound 
fraction was eluted from the column by gravity followed by washes with phosphate buffered 
saline. The bound fraction was then eluted from the columns with 3 mol/L sodium 
thiocyanate in phosphate-buffered saline. The efficiency of the immunoaffinity separation 
(percent of apoA-II removed from plasma by the resin) was 93%.The two immunofractions 
were then fractionated by density ultracentrifugation9. The fractions were centrifuged in an 
L8–70M instrument (Beckman, Brea, CA) equipped with a Ti25 rotor for 1 hour at 
25,000rpm to float light VLDLs [Svedberg units of flotation (Sf) 60–400]. After light VLDL 
was collected by aspiration, the initial volume was restored with d=1.006 g/mL phosphate 
buffered saline and dense VLDL (Sf: 20–60) was isolated by spinning for 16 hours at 
25,000rpm. Following collection of dense VLDL, the initial volume was restored with 
potassium bromide (KBr) solution to simultaneously adjust the density to 1.025 g/mL. The 
samples were then spun at 25,000rpm for 16 hours to isolate IDL (1.006–1.025 g/mL). 
Finally, after IDL was collected, the sample density was again adjusted with KBr to 1.050 
g/mL, the samples were spun for 24 hours at 25,000rpm, and LDL (1.025–1.050) was 
collected.
We combined light and dense VLDL data because the individual concentrations and tracer 
enrichments were too low for reliable measurement. Also, in this population, apoA-II 
concentrations in LDL were near or below the detection limit (0.001mg/dL), not exceeding 
0.01mg/dL or 0.5% of total for any individual. Furthermore, the percentage of LDL apoB 
that contained apoA-II was less than 1% and was not detectable in most samples by GC-MS. 
Therefore, this study focused on apoB lipoproteins in the VLDL and IDL fractions. In this 
study, VLDL and IDL refer to the lipoproteins present in the respective density fractions, 
both apoB48 and apoB100.
Measurement of apoB Tracer Enrichment and Pool Size
ApoB was precipitated from the lipoproteins with isopropanol, a norleucine internal 
standard was added, and the mixture was converted to volatile heptafluorobutyric acid 
derivatives. Measurement of tracer enrichment was done as previously described.9 Tracer 
enrichment was measured on a 6890 gas chromatograph/5973 mass spectrometer (Hewlett-
Packard, Palo Alto, CA) using negative chemical ionization and selective ion monitoring. 
ApoB mass was measured by comparing the ratio between the area under the leucine curve 
and the area under the norleucine curve with a standard curve of various leucine/norleucine 
ratios. The ratio calculated in the sample is converted to a concentration of leucine using the 
equation from the standard curve. The leucine mass is converted to concentration of apoB in 
the injected sample using the proportion of apoB that is leucine and dividing by the total 
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volume of plasma in the original starting sample. ApoB mass is calculated by multiplying 
the apoB concentration by the subject’s total plasma volume, which is estimated using their 
weight in kilograms. Plasma volume (L) was assumed to be 4.4% of body weight (kg) for 
groups with an average BMI <30 kg/m2. For the obese group (BMI>30 kg/m2) plasma 
volume was calculated based by an equation described by Nikkila and Kekki.10 To evaluate 
the possibility of degradation occurring in the samples, we compared the apoB concentration 
in the samples used in the present study to samples stored at −80C less than 1 year. In our 
study 0.10% of total apoB was in the VLDL fraction with apoA-II versus 0.08% in the 
newer samples. We found similar results in the IDL fraction, in our study 0.12% of total 
apoB was in the IDL fraction with apoA-II versus 0.15% in the newer samples. These results 
show that with longer storage significant degradation is unlikely.
Model Development and Kinetic Analysis
A multi-compartment model was used to describe VLDL and IDL apoB kinetics. The 
SAAM II software (The Epsilon Group, Charlottesville, VA) was used to model the data. 
The model allowed for direct secretion into VLDL and IDL fractions, as well as direct 
clearance from the corresponding compartment. The VLDL and IDL apoB fractional 
catabolic rates (FCR) were determined from the model parameters giving the best fit. Since 
VLDL metabolism is a multiple pool process, as part of our model development process, we 
tested for multiple pools of VLDL and IDL within subfractions that contain apoA-II, as well 
as conversion pathways among lipoproteins of different apoA-II content.
Statistical analyses
Weight and BMI, as well as serum total cholesterol, triglyceride, and HDL cholesterol were 
summarized by mean ± standard deviation for each diet group separately. Outcomes of 
interest included fractional catabolic rate, percent lipolytic conversion from VLDL to IDL, 
percent clearance of VLDL, and molar ratio of VLDL and IDL constituents per apoB. The 
difference for each outcome with and without apoA-II was calculated separately for VLDL 
and IDL, and the mean within-group paired difference tested against the null hypothesis of 
zero using paired t-test. All tests were two-sided, and deemed statistically significant at 
P<0.05.
Results
Results of Modeling
The model utilized a plasma amino acid forcing function followed by a delay compartment 
to account for the time required for synthesis and secretion of apoB into plasma. We tested 
for conversion pathways among lipoproteins of different apoA-II composition, specifically, 
A-II(+) VLDL→A-II(−) IDL as well as A-II(−) VLDL→A-II(+) VLDL. We also tested two 
models with multiple VLDL pools. The models and summaries of results are included in the 
supplementary online appendix. The tracer data did not support the presence of such 
conversion pathways or multiple VLDL pools and this was reflected by poor precision of 
model parameters. The two multiple VLDL pool models we tested gave similar results to a 
single VLDL pool model but with higher CVs. One of the models allowed for conversion 
from the first VLDL pool to a second VLDL pool or IDL. A second model allowed 
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conversion from the first VLDL pool to a second VLDL pool and then from the second 
VLDL pool to IDL. Consequently, we had abided by the principle of parsimony, which was 
to select the model with the least numbers of parameters that fit the data best.11 The 
precision of our final model parameters were relatively high with CVs averaged over the 
four density fractions of <25%. The final model is shown in Figure 1. The tracer-to-tracee 
ratios and pool sizes in VLDL and IDL fractions are provided in Figure 2.
Subject Characteristics
Eleven participants (5 men and 6 women) had mean body mass index of 30 ± 5 kg/m2, total 
cholesterol of 208 ± 35 mg/dL, fasting triglyceride (TG) of 174 ± 103mg/dL, and HDL 
cholesterol of 50 ± 21 mg/dL (Table 1).
A small fraction of total VLDL and IDL apoB contains apoA-II
Mean concentration of apoB in VLDL with apoA-II was 0.42 ± 0.10 mg/dL, compared to 
5.27 ± 3.16 mg/dL for VLDL without apoA-II,(mean paired difference = 4.84 ± 3.07, 
P=0.05). Thus, VLDL with apoA-II comprised 7% of total VLDL apoB. Mean 
concentration of apoB in IDL with apoA-II was 0.23 ± 0.16 mg/dL compared to 2.39 ± 2.07 
mg/dL for IDL without apoA-II, representing 9% of total IDL apoB.
Direct secretion rates of apoB in VLDL and IDL with apoA-II were lower than VLDL and IDL 
without apoA-II
ApoB secretion rates of VLDL with apoA-II were significantly lower than VLDL without 
apoA-II (Figure 3B). The secretion rate of VLDL with apoA-II was 0.45 mg/kg/day, which 
represents 4.5% of secreted VLDL apoB, compared to 10.7 mg/kg/day (86%) for VLDL 
without apoA-II. Secretion of IDL with apoA-II was lower than that of VLDL with apoA-II, 
1.5% of total IDL apoB.
VLDL apoB with apoA-II has a slow fractional catabolic rate
VLDL with apoA-II had a slower apoB fractional catabolic rate (FCR) than VLDL without 
apoA-II, 2.80 ± 0.96 pools/day vs. 5.09 ± 1.69 pools/day (mean difference −2.29 ± 0.75 
pools/day; P=0.009) (Figure 4A,C). In contrast, the mean FCR for IDL without apoA-II was 
similar to that for IDL with apoA-II, mean difference, 1.29 ± 2.55 (P=0.39) (Figure 4B,C).
Most VLDL containing apoA-II are converted to IDL before clearance from the circulation
A larger percentage of VLDL with apoA-II compared to VLDL without apoA-II underwent 
conversion by lipolysis to IDL rather than clearance from the circulation, 96 ± 8% vs. 45 ± 
22% respectively (mean difference 51.4 ± 15.1% P=0.007). Only 4% of VLDL with apoA-II 
left the circulation without becoming IDL, compared to 55% to VLDL without apoA-II. The 
rate constants for conversion of VLDL to IDL were similar for the VLDL with and without 
apoA-II (2.67 ± 93 pools/day vs. 2.14 ± 1.14), whereas the rate constants for clearance of 
VLDL with apoA-II were greatly reduced (Figure 3A). Flux percentages are shown in 
Figure 3B. Percent conversion to IDL, percent VLDL clearance, and mean differences for 
the groups is shown in Figures 4 D, E, and F respectively.
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Triglyceride, Cholesterol, and Apolipoprotein Content of VLDL and IDL
The mean apoC-III/apoB molar ratio was 27 ± 12 for VLDL without apoA-II versus 86 ± 37 
for VLDL with apoA-II (P=0.02); and for IDL 19 ± 12 versus 75 ± 40 (P=0.06) (Table 2). 
The Spearman rank correlation of FCR and apoC-III content is −0.81 for VLDL and 0.62 for 
IDL. The mean apoE/apoB molar ratio was 4 ± 1 for VLDL without apoA-II versus 23 ± 4 
for VLDL with apoA-II (P=0.004); and for IDL 3 ± 1 versus 7 ± 4 (P=0.05). VLDL with 
apoA-II tended to have a lower TG/apoB ratio and a higher cholesterol/apoB ratio than 
VLDL without apoA-II but the differences were not statistically significant (Table 2).
Discussion
The main findings are that the plasma apoB pool size of VLDL containing apoA-II is much 
smaller than that of VLDL without apoA-II, and this was caused by a very low rate of 
secretion of this VLDL type into plasma. This low rate of secretion was sufficiently low to 
compensate for a slower FCR of VLDL with apoA-II which would tend to increase the pool 
size. The slow FCR of VLDL with apoA-II is accounted for by greatly reduced clearance 
from plasma, and not by slow lipolytic conversion to IDL.
ApoA-II overexpression in mice produces VLDL that is a poor substrate for lipoprotein 
lipase in assays performed in vitro. 4,5 However, hydrolysis of VLDL-TG in vivo in the 
apoA-II overexpressing mice was similar to control mice.6,12 Alaupovic et al. found that 
VLDL from patients with Tangier disease had high contents of apoA-II and were less 
effective as a substrate for human milk lipoprotein lipase than VLDL from normal controls.7 
However, other compositional differences of Tangiers VLDL complicates attribution of 
slow lipolysis specifically to high apoA-II. Alaupovic et al subsequently used apoA-II 
immunoabsorbers to discover in 3 patients with Tangier disease and in 3 patients with severe 
hypertriglyceridemia (Type V Hyperlipoproteinemia) a discrete subspecies of VLDL that 
contained high amounts of apoA-II in combination with apoC-I, apoC-II, apoC-III apoD and 
apoE. They found in the patients with severe hypertriglyceridemia that the lipolysis rate in 
vitro of VLDL that contained apoA-II was about 50% slower than VLDL that did not 
contain apoA-II.3 VLDL with apoA-II from Tangier disease also showed a slow rate of 
lipolysis, although the researchers did not study VLDL without apoA-II in the Tangier 
patients. Therefore, we hypothesized that apoA-II reduces the conversion rate of VLDL to 
IDL, a process that involves lipoprotein lipase. We found to the contrary that VLDL with 
apoA-II in our normolipidemic and mildly hypertriglyceridemic participants does not have a 
slower conversion rate to IDL, in vivo, compared to the same participants' VLDL that did 
not have apoA-II. The rate constants for conversion to IDL are similar for VLDL with and 
without apoA-II, and should reflect the activity not only of lipoprotein lipase but also of 
hepatic lipase. Normal conversion of VLDL to IDL in our human study is consistent with 
normal rate of hydrolysis of VLDL TG in mice overexpressing human apoA-II. 6,12 ApoA-II 
containing apoB lipoproteins comprise nearly 90% of the apoB lipoproteins in Tangiers 
disease and about 50% in severe hypertriglyceridemia, much greater amounts than in the 
normal or mildly hypertriglyceridemic participants in our study.7 It is possible that much 
higher apoA-II levels in VLDL than our participants had are needed to inhibit lipolysis.
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We found that VLDL with apoA-II are not effectively cleared from the circulation. TG 
content of VLDL with apoA-II is similar to that of VLDL without apoA-II. If VLDL with 
apoA-II inhibits lipoprotein lipase, the TG content should be much higher than VLDL 
without apoA-II. In mice overexpressing mouse apoA-II, clearance of chylomicrons, 
estimated by the retinyl palmitate method, is reduced.5 In mice overexpressing human apoA-
II, VLDL clearance rate measured by the cholesteryl oleyl ether method, is not affected.12 
These methods are not easily used to interpret in vivo metabolism of VLDL particles in 
humans which is measured directly by apoB kinetics. Our results suggest that once VLDL 
enters the circulation, the apoA-II content is a determinant of their flux distribution.
The contents of apoE and apoC-III per VLDL with apoA-II, as measured by their molar 
ratio to apoB, are higher in VLDL particles with apoA-II compared to VLDL without apoA-
II. Previous studies have found that apoA-II can form a complex with apoE on HDL and 
hypothetically it is possible that it does so on VLDL and reduces the ligand function of 
apoE.13 It is also possible that apoA-II interacts with apoE in a similar way as apoC-III 
blocking its interaction with hepatic receptors that remove VLDL from the circulation.8,12,13 
This may explain our finding of a slower rate constant for clearance of VLDL particles 
containing apoA-II from plasma. Alternatively, apoC-III itself may have played a role in 
reduced clearance of VLDL particles containing apoA-II. Previous human kinetic studies 
have established apoC-III strongly inhibits hepatic uptake of VLDL. 8 We found that the 
apoC-III to apoB ratio is associated inversely with VLDL FCR but directly with IDL FCR. 
In this small sample, it is not possible to determine the association of apoA-II with VLDL 
and IDL FCR independent of content of apoC-III.
Though we did not specifically isolate the chylomicron fraction, based on previous work in 
our lab the pool size of VLDL apoB-48 is much smaller than VLDL apoB-100 and once 
apoB-48 particles are in circulation the metabolic pathways and FCR become similar.14 
Thus, apo48 lipoproteins do not contribute materially to the metabolic rates of apoB in 
VLDL and IDL as prepared in our study.
Limitations of our study include a small sample size as well as pooling of plasma, inability 
to determine the role of apoA-II in VLDL and IDL that does not have other apolipoproteins 
such as apoC-III or apoA-I, and participants being on two different diets rather than a single 
diet. Another limitation was that plasma of participants had to be pooled due to insufficient 
quantity of plasma to test individuals. However, pooling of samples helps reduce inter-
individual variability. Additionally, further studies are needed, specifically with VLDL with 
apoA-II, but without other apolipoproteins if possible, to understand the unique effect of 
apoA-II. Diet influences metabolic pathways and secretion of triglyceride-rich lipoprotein 
particles.9 Nonetheless, the results pertaining to the metabolism of VLDL and IDL 
according to presence or absence of apoA-II were in the same direction for the two pools 
that came from participants who ate the low-fat diet and those on the high-monounsaturated 
fat diet. We found that the concentrations of VLDL and IDL that have both apoA-I and 
apoA-II are very low (results included in supplementary online appendix); we did not study 
the metabolism of this type of particle distinct from VLDL and IDL that have apoA-II but 
not apoA-I.
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In summary, a small percentage of VLDL and IDL contains apoA-II. VLDL containing 
apoA-II have a slower FCR and are less likely to be cleared from plasma and more likely to 
be converted to IDL. The conversion rate of VLDL to IDL is similar for VLDL that has or 
does not have apoA-II, suggesting that apoA-II does not inhibit lipolytic conversion of 
VLDL. Instead VLDL with apoA-II have a slow clearance rate from plasma, thus increasing 
the percentage that is converted to IDL. Our results have potential implications for 
understanding the dyslipidemia in familial combined hypercholesterolemia and type V 
hyperlipoproteinemia, as these phenotypes have significant hypertriglyceridemia. Given the 
poor clearance of VLDL containing apoA-II, the presence of apoA-II on VLDL may 
promote atherogenesis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• We studied the kinetics of VLDL with and without apoA-II in humans.
• A small percentage of VLDL and IDL contains apoA-II.
• VLDL with apoA-II has a slower FCR than VLDL without apoA-II.
• VLDL with apoA-II has greatly reduced clearance from plasma compared to 
VLDL without apoA-II.
• VLDL with apoA-II has similar rate of conversion to IDL as VLDL without 
apoA-II
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Figure 1. 
Structure of the model. Plasma apoB was separated into 4 different lipoprotein fractions 
(circles) by anti-apoA-II immunoaffinity chromatography and then ultracentrifugation. 
Plasma tracer forcing function is followed by a delay compartment. The delay compartment 
accounts for the time required for the synthesis and secretion of apoB into plasma. ApoA-
II(+) and apoA-II(−): denote lipoproteins that do or do not contain apoA-II, respectively.
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Figure 2. 
(A–D) Tracer enrichment of [D5]L-phenylalanine in apoB of VLDL and IDL. Lines 
represent model derived curves fit to the data points. (A,B) Monounsaturated fat diet and 
(C,D) Carbohydrate diet. ApoA-II(+) and apoA-II(−): denote lipoproteins that do or do not 
contain apoA-II, respectively.
(E–H) Measured apoB pool sizes and model-derived fits in VLDL and IDL. Subfractions on 
a monounsaturated fat (E,F) diet and on a carbohydrate diet. (G,H). ApoA-II(+) and apoA-
II(−): denote lipoproteins that do or do not contain apoA-II, respectively.
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Figure 3. 
Average rate flux distributions, pool size (mg), and rate constants (pools/day) of apoB 
lipoproteins. The rectangular box on the left represents the liver, and arrows out of this box 
represent direct liver secretion into plasma. The circles represent lipoprotein compartments. 
The numbers inside the circles indicate average measured pool size. Arrows out of the 
lipoprotein compartments represent conversion to IDL or removal from plasma. (A) 
Numbers above or next to the arrows represent average rate constants ± SD. (B) Italicized 
percentages indicate percentage of total liver secretion into each compartment ± SD. 
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Percentages above or below the arrows indicate the relative proportion of flux out of each 
compartment. ApoA-II(+) and apoA-II(−): denote lipoproteins that do or do not contain 
apoA-II, respectively. See Figure 4 and text for statistics.
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Figure 4. 
Paired observations for (A) Fractional catabolic rate (FCR) VLDL, (B) FCR IDL, (C) Box 
plots showing mean paired difference in FCR for VLDL and IDL that do or do not contain 
apoA-II. (D) Percent conversion of VLDL to IDL, (E) Percent clearance of VLDL, (F) Box 
plots showing paired differences for conversion of VLDL to IDL and clearance of VLDL. 
Differences are apoA-II(+) minus apoA-II(−). ApoA-II(+) and apoA-II(−): denote 
lipoproteins that do or do not contain apoA-II, respectively. Each box-whisker plot 
represents the sample mean (diamond), median (center line), lower quartile (bottom of the 
box), upper quartile (top of the box), and extremes (vertical whiskers) outside the 
interquartile range.
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